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1. Introduction  
Cryptosporidiosis is a disease caused by Cryptosporidium spp, an obligate intracellular 
protozoan parasite.  
It is a frequent cause of diarrheal disease in humans, and several groups of humans are 
particularly susceptible to cryptosporidiosis. In developing countries, Cryptosporidium 
infections occur mostly in children younger than 5 years (Newman et al, 1999; Bern et al, 
2000; Bhattacharya et al, 1997; Gatei et al, 2006). In immunocompromised persons such as 
human immunodeficiency virus-positive (HIV) patients, the incidence and severity of 
cryptosporidiosis increases as the CD4 lymphocyte cell count falls (Navin et al, 1999; Pozio 
et al, 1997; Sorvillo et al, 1998). 
Although cryptosporidiosis was initially described in mice in 1907 (Tyzzer, 1907), human 
disease was first identified almost three quarters of a century later. Two reports were 
published in 1976: one case in healthy child and one in an immunosuppressed adult (Meisel 
et al, 1976; Nime et al, 1976). 
The next significant milestone was the emergence of chronic and life-threatening 
cryptosporidiosis with HIV/AIDS in the early 1980s. The association with AIDS and the 
appearance of early clinical and epidemiological reports implicating cryptosporidiosis as a 
frequent cause of acute diarrhea in the general population firmly established that the 
infection was serious and widespread in humans. The first case of cryptosporidiosis in a 
homosexual man with AIDS was reported in 1982 (Ma & Soave, 1983) and by mid-1983, 
some 50 cases had been reported (Ma, 1984). The link with AIDS was so strong that 
cryptosporidiosis became one of the defining features of the syndrome before the discovery 
of the causative virus.  
Then, other immunocompromised patients and healthy people including veterinary 
workers and children were also diagnosed with cryptosporidiosis.  
Cryptosporidiosis is an opportunistic parasitosis. It is characterised by self-limiting 
gastroenteritis in otherwise healthy people, while it is more severe in immunocompromised 
subjects in HIV-infected patients and constitutes a serious threat leading to chronic or 
fulminant disease, wasting and death (Hunter & Nichols, 2002; Chen et al, 2002). 
While improved antiretroviral regimens have significantly reduced the prevalence of AIDS 
and AIDS-related opportunistic infections, cryptosporidiosis remains among the most 
common causes of diarrhoea in patients with AIDS (Hunter & Nichols, 2002; Morpeth & 
Thielman, 2006). 
www.intechopen.com
 
Microbes, Viruses and Parasites in AIDS Process 
 
290 
During the three last decades our knowledge about cryptosporidiosis has expanded 
remarkably.  
The focus of this revue is to summarize current knowledge on taxonomy, epidemiology, 
diagnosis, treatment and prevention of cryptosporidiosis in AIDS patients.  
2. Parasite 
2.1 Taxonomy 
Cryptosporidium species are apicomplexan parasites.  
Over 100 years have passed since Ernest Edward Tyzzer first made his observations on the 
genus Cryptosporidium. Cryptosporidium was so named because of the absence of sporocysts 
within the oocysts, a characteristic of other coccidia. The first species described was C. muris, 
from the gastric glands of laboratory mice (Tyzzer, 1907). Tyzzer later published a more 
complete description of the life cycle and subsequently described a second species, also from 
laboratory mice. C. parvum differed from C. muris not only by infecting the small intestine 
rather than the stomach but also because the oocysts were smaller (Tyzzer, 1910, 1912).  
Following the initial discovery of Cryptosporidium, over 50 years elapsed during which the 
parasite was commonly confused with other apicomplexan genera, especially members of 
the coccidian genus Sarcocystis. 
After the recognition of true differences between Cryptosporidium and Sarcocystis, the 
erroneous concept of strict host specificity was applied to Cryptosporidium spp. This led to 
the creation of multiple new species including C. agni in sheep, C. anserinum in geese, C. 
bovis in calves, C. cuniculus in rabbits, C. garnhami in humans, and C. rhesi in monkeys 
(Levine, 1980; Barker & Carbonell, 1974). 
Subsequent cross-transmission studies demonstrated that Cryptosporidium isolates from 
different animals can frequently be transmitted from one host species to another, which 
ended the practice of naming species based on host origin and the synonymization of many 
of these new Cryptosporidium species as C. parvum. 
In recent years, molecular characterizations of Cryptosporidium have helped to clarify the 
confusion in Cryptosporidium taxonomy and validate the existence of multiple species in 
each vertebrate class.  
As a result, several new species of Cryptosporidium have also been named, C. andersoni from 
cattle, C. canis from dogs, C. molnari from fish and C. hominis from humans (Xiao et al, 2004; 
Alvarez-Pellitero & Sitja-Bobadilla, 2002; Lindsay et al, 2000; Morgan-Ryan et al, 2002). 
Human disease has been traditionally attributed to C. parvum but it was apparent from both 
the early epidemiological questions raised regarding the zoonotic status and transmission of 
the organism that variants occurred.  
C. parvum, C. hominis were two confused species. The first observations of genetic 
heterogeneity among C. parvum (currently C. parvum and C. hominis) isolated from humans 
and livestock date back to 1992. Southern blotting of restriction enzyme-digested genomic 
DNA (Ortega et al, 1991), Western blotting (Nina et al, 1991) and isoenzyme profiles 
obtained from oocyst lysates (Ogunkolade et al, 1993) provided the first insights into the 
extent of heterogeneity in this species. Significantly, these studies showed for the first time 
that humans were infected with two subgroups within C. parvum, which were variously 
named “human” and “cattle”, H and C or Type 1 and Type 2, respectively. These 
observations, subsequently confirmed in many laboratories, were significant in showing that 
humans are part of two distinct transmission cycles, one comprising ruminants and humans 
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ant the other exclusively comprising humans. It was a small step to the naming of a new 
species, C. hominis, proposed for C.parvum parasites exclusively infecting humans (Spano et 
al, 1998; Morgan-Ryan et al, 2002).  
There are currently 16 recognized species of Cryptosporidium, which have been isolated from 
a large variety of hosts (Table 1), (Xiao et al, 2004) : C. parvum, C. hominis, C. felis, C. canis, C. 
wrairi, C. varanii, C. suis, C. bovis, C. andersoni, C. muris, C. serpentis, C. galli, C. meleagridis, C. 
molnari, C. scophithalmi and C. baileyi. The four basic requirements for the naming of 
Cryptosporidium species are (Xiao, 2010; Chalmers, 2008): 
1. Morphometric study of oocysts and, if possible, sporozoites. 
2. Multi-locus genetic characterisation by nucleotide sequence analysis of well studied 
genes or non-coding regions. The ssu rRNA gene is usually included. 
3. Demonstration of natural and, if possible, experimental, host specificity. 
4. Compliance with the International Code of Zoonotic Nomenclature.   
Eight species are known to be infectious for man: C. parvum, C. hominis, C. meleagridis, C. 
 
Species  
 
Major host Minor host Location 
C. muris  
 
Rodents, bactrian 
camels 
Humans, rock hyrax, 
mountain goat 
Stomach 
C. andersoni  Cattle, bactrian 
camels 
Sheep Abomasums 
C. parvum  
 
Cattle, sheep, goats, 
humans 
Deer, mice, pigs Stomach and intestine 
C. hominis  Humans, monkeys Dugongs, sheep Small intestine 
C. wrairi  Guinea, pigs  Small intestine 
C. felis  Cats Humans, cattle Small intestine 
C. canis  Dogs Humans Small intestine 
C. meleagridis  Turkeys, humans Parrots Intestine  
C. baileyi  Chicken, turkeys Cockatiels, quails, 
ostriches, ducks 
Cloacal, bursa, 
respiratory tract 
C. galli  Finches, chicken, 
capercalles, 
grosbeaks 
 Proventriculus  
C. serpentis  Snakes, lizards  Intestinal and cloacal 
mucosal 
C. scophithalmi  Fish  Intestine 
C. molnari  Fish  Stomach 
C. varanii  Snakes, lizards  Intestinal and cloacal 
mucosal 
C. suis  Pigs humans Stomach 
C. bovis Ruminants  Intestine 
Table 1. Recorded species of Cryptosporidium  
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felis, C. canis, C. suis, C. muris and C. andersoni, although some are reported extremely 
rarely, particularly the latter three species, and the pathogenicity of some species for 
man has not been proven (Chalmers, 2008). 
C. hominis and C. parvum are recognized globally as the most important Cryptosporidium 
species infecting humans (Dunand et al, 1997; Xiao & Ryan, 2004). 
Muthusamy et al characterized cryptosporidial infections in 48 human 
immunodeficiency virus-infected individuals in india by multilocus genotyping. C. 
hominis, C. parvum, C. felis, C. muris and C. meleagridis were identified (Muthusamy et al, 
2006).  
2.2 Life-cycle 
Sporulated oocysts, containing 4 sporozoites, are excreted by the infected host through feces 
and possibly other routes such as respiratory secretions. Following ingestion (and possibly 
inhalation) by a suitable host, excystation occurs. The sporozoites are released and parasitize 
epithelial cells of the gastrointestinal tract or other tissues such as the respiratory tract.  
Cell invasion by sporozoites is followed by intracellular development to trophozoite.  
In these cells, trophozoites undergo asexual multiplication (schizogony or merogony) to 
form schizonts or meronts.  
Asexual replication occurs by re-infection of merozoites, released by type I meronts. 
Development of type II from type I meronts is the initial step of the asexual reproductive 
cycle. Merozoites are released from type II meronts and re-infect neighbouring cells where 
they develop into producing microgamonts (male) and macrogamonts (female) by sexual 
multiplication (gametogony). Upon fertilization of the macrogamont by the microgamont 
zygote develop, which undergoes further development into an oocyst.  
Two different types of oocysts are produced, the thick-walled, which is commonly excreted 
from the host, and the thin-walled oocyst, which is primarily involved in autoinfection. 
Oocysts are infective upon excretion, thus permitting direct and immediate fecal-oral 
transmission. 
3. Epidemiology 
3.1 Risk factors 
The risk of infection increases in more profoundly immunosuppressed persons, as measured 
by the CD4 T-lymphocyte counts (Houpt et al, 2005).  
The incidence and severity of cryptosporidiosis increases as the CD4 T-lymphocyte cell 
count falls, especially when it falls to below 200 cells/l (Navin et al, 1999; Pozio et al, 1997; 
Sorvillo et al, 1999; Sara et al, 2008). 
Various social and behavioral factors also increase the risk of infection. For example, in a 
large multicenter European study, the risk of cryptosporidiosis was significantly lower for 
intravenous drug users than for homosexual men and for women than for men, suggesting 
that sexual behaviour may be an important risk factor (Pedersen et al, 1996).  
3.2 Modes of transmission 
Transmission of the parasite is facilitated by a relatively low infectious dose and by the 
resistance of the parasite oocyst stage to commonly used disinfection techniques e.g 
chlorination of dinking water. 
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The infection is spread in a number of ways: from person to person, from animals, via food, 
and by water. Cryptosporidiosis is now the most common cause of waterborne disease in 
the world (Xiao & al, 2004).  
Because Cryptosporidium spp. infects humans and a wide variety of animals and because of 
the ubiquitous presence of Cryptosporidium oocysts in the environment, humans can acquire 
Cryptosporidium infections through several transmission routes (Clark, 1999; Griffiths, 1998). 
In pediatric and elderly populations, especially in day care centers and nursing homes, 
person-to-person transmission probably plays a major role in the spread of Cryptosporidium 
infections (Xiao L et al, 2004; Neill et al, 1996; Tangermann, 1991). In rural areas, zoonotic 
infections via direct contact with farm animals have been reported many times, but the 
relative importance of direct zoonotic transmission of cryptosporidiosis is not entirely clear 
(Miron et al, 1991). 
Numerous outbreaks of cryptosporidiosis due to contaminated food or water (drinking or 
recreational) have been reported in several industrialized nations, and studies have 
sometimes identified water as a major route of Cryptosporidium transmission in areas where 
the disease is endemic (Xiao et al, 2004; MacKenzie et al, 1991; Weinstein et al, 1993 ). 
Many outbreaks in the United States have occurred in waterparks, community swimming 
pools, and day care centers.   
Large outbreaks due to the contamination of water supplies have been documented in 
recent years (Richardson et al, 1991; Tzipori & Giovanni, 2008) and in one particular 
outbreak, contamination of a water–treatment plant in Milwaukee (USA) was estimated to 
result in infections in 403 000 people ( Mac Kenzie et al, 1994).  This outbreak was associated 
with municipal drinking water despite state-of-the art water treatment.  
The magnitude of these outbreaks highlighted the significance of drinking contaminated 
water as a major risk factor for contracting cryptosporidiosis in the USA (Tzipori & 
Giovanni, 2008). 
The sources and human infective potentials of Cryptosporidium oocysts in water, however, 
are largely unclear. 
One major problem in understanding the transmission of Cryptosporidium infection is the 
lack of morphologic features that clearly differentiate one Cryptosporidium spp from many 
others (Mac Kenzie et al, 1994). Hence, one cannot be sure which Cryptosporidium spp is 
involved when one examines oocysts in clinical specimens under a microscope. Another 
major problem is the inability to grow the organisms in large numbers from contaminated 
sources. Adding to the diagnosis problem and technical difficulties is the confusion in the 
taxonomy of Cryptosporidium spp., which is partially caused by the lack of consistency in the 
classification of protozoan parasites in general. 
C. hominis is believed to be transmitted exclusively between humans, whereas C. parvum is 
transmitted between humans as well as through a zoonotic cycle usually involving 
ruminants. Although calves are often implicated as the reservoir of C. parvum, the 
importance of animals in transmission of C. parvum has been brought into question by 
studies that found that humans are infected with subtypes that perpetuate almost 
exclusively among humans (Siobhan & Tzipori, 2008). 
The study of Cryptosporidium transmission dynamics is made more complex when atypical 
species are considered. Human infections with C. meleagridis, C. muris, C. felis, C. canis, C. 
andersoni and C. suis, though uncommon, have been reported (Mor MS & Tzipori, 2008; Xiao 
& Ryan, 2004). 
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The natural reservoirs of these species are believed to be poultry, rodents, cats, dogs, cattle, 
and pigs, respectively; however the broad host ranges are not well characterized. Host 
factors may also increase the likelihood of infection following exposure to these species, 
because they are more frequently identified in HIV-positive persons. Two recent studies in 
East Africa have attempted to correlate species diversity with area of residence. In Malawi, 
C. meleagridis and C. andersoni were detected only in children from a rural district, although 
70% of C. parvum cases were identified in urban areas and C. hominis predominated in both 
settings (Mor & Tzipori, 2008; Mersha & Tiruneh, 1992). In Kenyan children, 4% of cases 
were due to C. canis, C. felis, C. meleagridis and C. muris, and there was no discernible 
difference by region (Gatei et al, 2006). 
4. Clinical features 
4.1 Gastrointestinal diseases 
Cryptosporidium species infect the microvillus border of the gastrointestinal epithelium of a 
wide range of vertebrate hosts, including humans. Infected individuals show a wide 
spectrum of clinical presentations. The pathogenicity of Cryptosporidium varies with the 
species of parasites involved and the type, age and immune status of the hosts.  
In immunocompetent subjects, cryptosporidiosis is characterized by watery or mucoid 
diarrhoea and abdominal pain with spontaneous recovery following several days or weeks 
of symptoms (Mersha & Tiruneh, 1992).  
Immunocompetent hosts control and eliminate the infection, which typically causes acute, 
self-limited watery diarrhea lasting 5 to 10 days. However, in patients with defects in 
cellular immune responses (e.g. AIDS), Cryptosporidium spp frequently causes persistent or 
chronic diarrhea which can lead to death and can also involve the hepatobiliary and the 
respiratory tract. It is an opportunistic infection.  
The risk of infection increases in more profoundly immunosuppressed persons, as measured 
by the CD4-T-lymphocyte counts (Houpt et al, 2005; Morpeth & Thielman, 2006). 
Various presentations of cryptosporidiosis in HIV-positive patients were described 
(Blanshard et al, 1992; Mc Gowan et al, 1993; Manabe et al, 1998).  
U.S. workers described four clinical syndromes: chronic diarrhea (affecting 36% of patients), 
cholera-like disease (33%), transient diarrhea (15%), and relapsing illness (15%) (Blanshard 
et al, 1992, Manabe et al, 1998). Infected patients had a significantly shorter duration of 
survival from the time of diagnosis than did Cryptosporidium-negative AIDS patients (240 
and 666 days, respectively; P = 0.0004).  
One aspect of chronic cryptosporidiosis in patients with AIDS is the large weight loss that 
many experience (Blanshard et al, 1992). One study from France reported that the severity of 
weight loss in such patients is independently associated with levels of nutrient intake (P < 
0.005) and high stool frequency (P < 0.01) but not with nutrient malabsorption (Beaugerie et 
al, 1998). 
As well as developing a more severe form of typical gastrointestinal disease, people with 
HIV infection can develop atypical disease presentations, affecting body systems not usually 
affected in immunocompetent individuals. Some of these unusual presentations are 
discussed below. 
4.2 Atypical gastrointestinal disease 
Many cases of gastritis were described. One particularly problematic complication of gastric 
involvement is antral narrowing and gastric outlet obstruction (Iribarren et al, 1997; Moon et 
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al, 1999). Such gastric outlet obstruction can lead to nausea and vomiting and eventually 
may cause a severe reduction in nutrient intake. 
A further unusual complication of cryptosporidiosis in AIDS patients is pneumatosis 
cystoides intestinalis (Samson & Brown, 1996; Sidhu et al, 1994). This disease is 
characterized by the presence of thin-walled, gas-containing cysts in the intestinal wall. 
Sometimes these cysts can rupture, resulting in a pneumoretroperitoneum and 
pneumomediastinum. 
There is a case report of cryptosporidiosis affecting the oesophagus in a 2-year-old child and 
resulting in vomiting and dysphagia (Kazlow et al, 1986). Finally, there is also a case report 
of Cryptosporidium infection causing appendicitis (Oberhuber et al, 1991). The diagnosis was 
confirmed histologically after an appendectomy was performed. 
4.3 Biliary tract disease 
Cholangitis, and particularly sclerosing cholangitis, is an important complication of AIDS. 
Although not appearing to adversely affect survival, the disease can be a cause of significant 
pain (Forbes et al, 1993). In a Spanish study of 43 AIDS patients with chronic diarrhea due to 
Cryptosporidium infection, 8 patients (18.6%) were reported to have Cryptosporidium infection 
of the common bile duct (Lopez-Velez et al, 1995). 
4.4 Pancreatitis 
A series of 15 autopsies on patients with AIDS and cryptosporidiosis showed that five had 
evidence of infection of the pancreas (Godwin et al, 1991). Histological changes were 
generally mild and were limited to hyperplastic squamous metaplasia. 
Three people with AIDS presented with acute or chronic pancreatitis related to 
cryptosporidiosis (Calzetti et al, 1997). All three patients had abdominal pain resistant to 
analgesics, increased serum amylase levels, and abnormalities at both sonography and 
computed tomography. Endoscopic retrograde cholangiopancreotography revealed 
papillary stenosis in all three patients. It is difficult to assess the impact of cryptosporidiosis-
related pancreatic disease. Certainly, the first study does not suggest significant morbidity 
due to Cryptosporidium in the pancreas (Hunter & Nichols, 2002). 
4.5 Respiratory tract disease 
In a study from Spain, 7 of 43 patients (16.3%) with chronic diarrhea due to Cryptosporidium 
had Cryptosporidium oocysts detectable in the sputum (Lopez-Velez et al, 1995). Of these 
seven patients, five had respiratory symptoms and an abnormal chest radiograph; 
Mycobacterium tuberculosis was isolated in two of the five, and M. avium was isolated in 
another two. The remaining two patients had no respiratory symptoms and normal chest 
radiographs. 
Other case series of patients with respiratory cryptosporidiosis were reported (Clavel et al, 
1996; Hunter &  Nichols, 2002). The majority of whom had another pathogen detected. So, 
the exact role of Cryptosporidium in the respiratory symptoms is not clear.  
Dunand et al reported on 5 of their own cases and reviewed 14 other cases of parasitic 
sinusitis in HIV-positive patients from the literature (Dunand et al, 1997). Symptoms often 
included fever and chills in addition to local tenderness and discharge. Although the 
prognosis was frequently poor, this was due to other complications of HIV infection. 
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5. Diagnosis 
For intestinal cryptosporidiosis, a parasitological examination of the stools is not only 
readily accessible and repeatable, but also non invasive for the patient. Oocysts are 
eliminated at intermittent intervals so stool tests should be repeated three times at three-day 
intervals (Weber et al, 1991; John & Petri, 2006). 
Because of the small size of the Cryptosporidium oocysts, they are difficult to identify in fresh 
samples without specific coloration.  
Oocysts may be examined under phase-contrast microscopy after concentration by different 
techniques. Oocysts may be concentrated by the modified zinc sulfate centrifugal flotation 
technique or by Sheather’s sugar flotation. 
Another concentration technique involves formalin-ethyl acetate sedimentation followed by 
layering and flotation over hypertonic sodium chloride solution to separate oocysts from stool 
debris (Weber et al, 1991). Oocysts appear as highly refractile spherical bodies (4 to 6 µm).  
Several staining techniques can be used, applied to the swabs realized after concentration.  
Modified Ziehl Neelsen stain is the best staining technique. The oocysts appear as rose 
spherical elements and contain four sporozoites (fig 1). The background is stained blue or 
green depending on the counter-stain used (Fast Green, malachite green or aniline blue) 
(Weber et al, 1991; Sunnotel et al, 2006). 
 
 
Fig. 1. Oocysts of Cryptosporidium sp stained by Modified Ziehl Neelsen stain 
Cryptosporidium can also be detected by staining air-dried, methanol-fixed fecal smears with 
Giemsa’s stain. 
More recently, detection of oocysts is made by the use of copro-antigen detection kits, such 
as immunofluorescent antibody stains for microscopy, enzyme linked immunosorbent 
assays (ELISA) or immunochromatographic tests (Johnston et al, 2003).  
Cryptosporidium oocysts also have been detected in fecal specimens by fluorescent stain like 
auramine-rhodamine.  
The analytical sensitivity of these methods is generally in excess of 104 oocysts per gram 
faeces, depending on faecal consistency (Anusz et al, 1990; Weber et al, 1991), although 
immunofluorescence microscopy offers improved sensitivity (Arrowood, 1997).  
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Cryptosporidiosis can be diagnosed by identifying organisms (meronts containing 
merozoites and gamonts containing micro- and macrogametes) in intestinal biopsy material. 
Organisms stain lightly with hematoxylin and eosin and appear as small round bodies on 
the mucosal surface of biopsy specimens. With Masson’s stain, a small red nucleus and blue 
cytoplasm can be distinguished in many of the organisms.  
Species identification is an important element of outbreak investigations particularly where 
the source is not clear, and it is important that this is underpinned by routine species 
identification to establish the background epidemiology (Chalmers, 2008). 
Even though oocysts of many Cryptosporidium spp are morphologically similar, 
morphometric measurement of oocysts can play a vital role in the differentiation of some 
Cryptosporidium spp. For example, the established species (interval) in birds and reptiles can 
easily be differentiated on the basis of the size and shape of oocysts. (Xiao et al, 2004).  
However, laboratory techniques are unable to discriminate between the two main species 
involved in human disease, C. hominis and C. parvum. Species identification can be achieved 
with molecular methods which provide a precious tool for detecting Cryptosporidium and 
differentiating species in biological samples of infected patients (Chalmers, 2008). 
However, Cryptosporidium presents two main problems for the isolation of DNA; the robust 
nature of the oocysts, requiring a disruption step prior to DNA extraction and the richness 
of PCR inhibitors in the sample matrix, requiring separation during DNA extraction. 
Currently, there is no international consensus of typing methods and many rely on DNA 
sequence analysis which can be time-consuming and costly (Chalmers, 2008).  
In 1991, Mark Laxer was the first to apply PCR to the detection of Cryptosporidium oocysts 
(Laxer et al, 1991). 
Among molecular methods, PCR combined with restriction fragment length polymorphism 
(PCR-RFLP), which was first applied to Cryptosporidium typing by Awad-El-Kariem (Awad-
El-Kariem et al, 1994) is the most used. PCR-RFLP assay detecting an RsaI polymorphism in 
the Cryptosporidium oocyst wall protein (COWP) gene (Spano et al, 1997), and a species-
specific assay targeting the small-subunit rRNA gene (Xiao et al, 1999) are the most popular.  
Papers describing such assays or their application to Cryptosporidium typing are too 
numerous to cite here. Other methods such as random amplification methods (Morgan et al, 
1995), sequencing (Lopez-Velez et al, 1995), length polymorphisms of repetitive sequences 
(Feng et al, 2000) and conformational polymorphism detection methods (Gasser et al, 2001) 
should also be mentioned in this context. However, the relatively high cost of molecular 
methods at present has limited their application in developed and developing countries.  
The methodologies used in the detection of Cryptosporidium-specific antibodies vary widely, 
which complicates comparison of results. The use of the recombinant CP 41 antigen in a 
standardized serodiagnostic assay could provide a reliable and cost-effective method for 
assessing human exposure to Cryptosporidium in developing countries (Kjos et al, 2005).  
6. Treatment 
Despite the importance of cryptosporidiosis in mondial health, there has been any effective 
therapeutic specifically against Cryptosporidium infection, probably because of the unique 
intracellular extracytoplasmic location of Cryptosporidium and the poorly understood host-
parasite interface. In addition, difficulties in laboratory propagation, including the absence 
of an ideal cell culture method, have limited high-throughput drug screening. Hundreds of 
drugs have been tested in the laboratory, and putative reports suggest that several, 
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including paromomycin, macrolides (e.g., azithromycin and spiramycin) and albendazole, 
are partially effective (Mor & Tzipori, 2008; Tzipori, 1998). 
Clinical evaluations of these drugs have been disappointing, largely because they failed to 
clear the parasite from patients with HIV/AIDS. 
To date, the broad-spectrum, anti-infective nitazoxanide (NTZ) has shown the most promise 
against Cryptosporidium (Mor & Tzipori, 2008). 
It is used in many areas of the world because it appears to be well tolerated, it has a 
relatively low incidence of adverse effects, and it displays no significant known drug-to-
drug interactions (Bobak, 2006). However, it is not effective against cryptosporidiosis in 
immunocompromised persons.  
A meta-analysis of randomized, placebo-controlled trial of NTZ (of which there are only 2) 
among immunocompromised patients concluded that NTZ was no more effective than 
placebo in resolving diarrhea and achieving parasitological clearance in HIV-positive 
persons (Abubakar, 2007). 
 It has been speculated that HIV-positive persons may benefit from longer-duration 
regimens or higher doses of NTZ.  However, a sustained clinical response was observed in 
only 59% of patients with HIV/AIDS who received off-label NTZ in a compassionate-use 
program (Rossignol, 2006). 
This study indicate that the drug should be administered 500 mg b.d. until clinical 
symptoms resolve and oocysts are eliminated from the stool. Doses may be escalated to 1000 
mg b.d. to accelerate or improve parasitological response. Fourteen days of treatment are 
generally sufficient in patients with CD4 counts above 50 cells/mm3 while at least 8 weeks 
of treatment are likely required in patients with CD4 counts below 50 cells/mm3. 
Although refinement of the dosing regimen may improve clinical efficacy of NTZ, a 
prolonged therapeutic course will be impracticable in developing countries because of the 
expense and likely patient noncompliance. 
ColoPlus is a product which may be an important alternative or additional treatment in 
HIV-associated diarrhoea. It is a product based on bovine colostrums witch is the first milk 
the suckling calf receives from the cow. It is rich in immunoglobulins, growth factors, 
antibacterial peptides and nutrients. It supplies the calf with a passive immunity before its 
own active immunity is established. As well as having a high nutritional value, it is 
designed for slow passage through the gastrointestinal tract.  
Floren et al conducted a study on thirty patients with HIV-associated diarrhoea. The 
patients were treated with ColoPlus for 4 weeks in an open-labelled non-randomised study, 
after an observational period of one week. After a post-treatment period of another two 
weeks, treatment with anti-HIV drugs was started, if deemed appropriate. The effects on the 
frequency of stool evacuations per day, on body-weight, fatigue, haemoglobin, levels and 
CD4 + counts before and after treatment with ColoPlus were measured. There was a 
dramatic decrease in stool evacuations per day, a substantial decrease in body-weight and 
an increase in CD4 count by 125 % (Floren et al, 2006). 
In part because of the failure of other therapeutic approaches, there have been several 
attempts at passive antibody-based immunotherapy for cryptosporidial infections (Crabb, 
1998). These have also had limited success.  
One therapeutic intervention that has a dramatic effect on cryptosporidiosis in AIDS 
patients is antiretroviral therapy leading to recovery of the CD4 count. (Foudraine, 1998; 
Maggi et al, 2000;  Miao et al, 2000; Morpeth & Thielman, 2006). The authors noted that 
resolution of the diarrhea seemed to be related to an increased CD4 - cell count rather than 
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to the viral load. These findings give further support to the observation that it is cellular 
immunity that is of paramount importance in clearing Cryptosporidium infection. 
7. Prophylaxis 
Because of the risk of acquiring a life-threatening disease, people with AIDS should take the 
following specific measures to help reduce the risk of waternborne cryptosporidiosis: boil 
drinking water for 1 minute, or filter drinking water with devices that remove particles 1 µm 
and larger, or use bottled drinking water, especially water obtained from underground 
sources (eg. springs or wells), which are less likely to be contamined by Cryptosporidium 
oocysts. However, the boiling of water is the most certain method of killing Cryptosporidium 
oocysts. They should take additional precautions, including avoiding contact with young 
pets, and avoiding swallowing water while swimming (John & Petri, 2006). 
The realization that Cryptosporidium oocysts are resistant to many chemical disinfectants 
(Tzipori & Giovanni, 2008; Rochelle et al, 2005) led to a search for methods that can 
inactivate oocysts without generating harmful by products. Much attention has focused on 
UV irradiation and ozone as alternative methods capable of inactivating waterborne oocysts 
(Tzipori & Giovanni, 2008; Lloyd & Drury, 2002). However, control of surface-water 
contamination is being emphasized as a first measure to reduce the occurrence of 
waterborne oocysts. Regulations aimed at reducing the risk of exposure to waterborne 
oocysts have been put in place; for example, the Long Term 2 Enhanced Surface Water 
Treatment Rule in the USA and regulations in the UK requiring continuous monitoring for 
Cryptosporidium oocysts in drinking water. A treatment-based standard of one oocyst in 10 l 
has been adopted (Sidhu et al, 1994). 
8. Conclusion 
We would conclude that research over the last three decades has dramatically increased our 
knowledge on cryptosporidiosis, but key questions still remain unclear.  
With the new interest in Cryptosporidium generated by the emergence of the latter as the 
cause of human disease, much research is ongoing and will provide continuing information 
concerning cryptosporidiosis in the future.  
Future developments need to include harmonisation of rapid and more cost effective 
methods.  
Effective therapies are likely to become available in the near future. Access to endogenous 
forms and immortalization of strains in culture or by cryopreservation remain major 
challenges, which will require new ideas and new approaches.  
Identification of Cryptosporidium isolates to species level and of subtyping is indispensable 
for appropriate control measures during outbreaks. 
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